Nature Biotechnology
- 24, 1105 - 1107 (2006)
doi:10.1038/nbt0906-1105
Impact of microarray data quality on genomic data submissions to the FDAFelix W Frueh
Felix W. Frueh, US Food and Drug Administration, Office of Clinical Pharmacology, Center for Drug Evaluationand Research, 10903 New Hampshire Avenue, Silver Spring, Maryland 20993, USA. felix.frueh@fda.hhs.gov
How can microarray data best be exploited and integrated into the regulatory decision-making process?
|
